Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR...

Area of Science:

• Molecular Biology
• Cancer Research
• Structural Biology

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are common in non-small cell lung cancer (NSCLC).
• Tyrosine kinase inhibitors (TKIs) target oncogenic EGFR, but drug resistance remains a significant challenge.
• The mechanisms by which EGFR mutations enhance ligand-independent signaling and promote cell survival are not fully understood.

Purpose of the Study:

• To elucidate how drug-resistant EGFR mutations promote ligand-independent auto-phosphorylation and cell survival.
• To investigate the structural basis and assembly mechanisms of ligand-free, kinase-active EGFR oligomers.
• To establish a link between ligand-free EGFR oligomerization and ligand-dependent tumor proliferation.

Main Methods:

• Structural analysis of EGFR oligomers.
• Investigation of EGFR assembly mechanisms.
• Biochemical assays to assess EGFR activity and ligand binding.

Main Results:

• Drug-resistant EGFR mutations induce the formation of stable, ligand-free, kinase-active oligomers.
• These oligomers utilize previously unrecognized transmembrane and kinase interfaces, as well as the ectodomain tethered conformation.
• Active dimer sub-units within ligand-free oligomers bind physiological ligand concentrations, linking ligand-free assembly to tumor growth and proliferation.

Conclusions:

• Ligand-free EGFR oligomerization is a key mechanism for oncogenic signaling in drug-resistant NSCLC.
• The identified oligomerization interfaces represent potential new targets for therapeutic intervention.
• Disrupting EGFR oligomer assembly could overcome TKI resistance and inhibit tumor growth.